Home / laxatives
Boldavera™
Boldavera™ is primarily used to eliminate constipation, but also for bloating, abdominal pain, belching, nausea, vomiting, bile, and gastric acid secretion disorders. The formula promotes peristalsis of the large intestine and have a mild laxative action. Boldavera™ is a complex herbal preparation containing boldin from the leaf of boldo and aloe dry extract. It has a cholagogic, antispasmodic and liver-protective action. It also increases the production of hydrochloric acid in the stomach. The anthracompounds present in the preparation promote the peristalsis of the large intestine and have a mild laxative action. That is why it is used in constipation, dyspeptic disorders, and symptoms of indigestion, such as bloating, abdominal pain, belching, nausea and vomiting.
Pharmacologic treatment of constipation: what is new?
Curr Opin Pharmacol. 2008 Dec;8(6):724-8. Epub 2008 Aug 20.
Pohl D, Tutuian R, Fried M.
Division of Gastroenterology and Hepatology, University Hospital of Zurich, Zurich, Switzerland.
Constipation is a common gastrointestinal disease affecting 2-27% of the population in Western hemisphere. Approximately in half of patients the diagnosis of functional constipation is made after having ruled out secondary causes. Treatment of chronic functional constipation primarily addresses education on toilet habits, dietary advice, and patient reassurance. Further therapies are guided according to functional subtype slow-transit constipation, dyssynergic defecation, and constipation-predominant irritable bowel syndrome (IBS-C).
Prevalence of atopy in children with chronic constipation.
Arch Dis Child. 2008 Dec;93(12):1044-7. Epub 2008 Jun 18.
Simeone D, Miele E, Boccia G, Marino A, Troncone R, Staiano A.
National Health Service, Pietrelcina (BN) and Trentola Ducenta (CE), Italy.
OBJECTIVES: To evaluate the prevalence of chronic constipation (CC) in unselected children, its association with atopy and the efficacy of a cow's milk protein (CMP) elimination diet on refractory constipation.
STUDY DESIGN: The study was conducted by six primary care paediatricians, serving a population of 5113 children aged from birth through to 12 years; only 2068 children were 6 months to 6 years.
Treatment of Chronic Constipation: Current Pharmacologic Approaches and Future Directions.
Clin Gastroenterol Hepatol. 2008 Dec 13.
Tack J, Müller-Lissner S.
Division of Gastroenterology, University Hospital, Leuven, Belgium.
Chronic constipation is a common condition that affects up to 27% of the population. Dietary and lifestyle measures are usually the first-line therapy, but if these fail to have an effect then a variety of prescription and consumer laxatives are available. Traditional laxatives include bulking agents, osmotic agents, stool softeners, and stimulants of the gastrointestinal tract.
Macrogol (polyethylene glycol) laxatives in children with functional constipation and faecal impaction: a systematic review.
Arch Dis Child. 2009 Feb;94(2):156-60. Epub 2008 Nov 19
Candy D, Belsey J.
Paediatric Gastroenterology Service, Royal West Sussex NHS Trust, Chichester PO19 6SE, UK. david.candy@rws-tr.nhs.uk
As the evidence base supporting the use of laxatives in children is very limited, we undertook an updated systematic review to clarify the issue. A comprehensive literature search was carried out to identify randomised controlled trials of polyethylene glycol (PEG) versus either placebo or active comparator, in patients aged <18 years with primary chronic constipation. Outcomes were assessed as either global assessments of effectiveness or differences in defaecation rates.
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study.
Aliment Pharmacol Ther. 2009 Feb 1;29(3):315-28. Epub 2008 Nov 8.
Quigley EM, Vandeplassche L, Kerstens R, Ausma J.
Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland. e.quigley@ucc.ie
BACKGROUND: Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL). AIM: A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, prucalopride, in patients with chronic constipation [
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
Gut. 2009 Mar;58(3):357-65. Epub 2008 Nov 5.
Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L.
Division of Gastroenterology, Department of Internal Medicine, University Hospital, Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. Jan.Tack@med.kuleuven.be
OBJECTIVE: To determine the efficacy, impact on quality of life (QOL) and safety of prucalopride, a selective, high-affinity 5-HT(4) receptor agonist, in patients with chronic constipation.
METHODS: In this multicentre, randomised, placebo controlled, parallel-group, phase III study, patients with chronic constipation (two or fewer spontaneous complete bowel movements (SCBM)/week) received 2 mg or 4 mg prucalopride or placebo, once daily, for 12 weeks.
Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight).
Acta Biomed. 2006; 77(3):157-62 (ISSN: 0392-4203)
Amenta M; Cascio MT; Di Fiore P; Venturini I
Centro di Prevenzione e Cura Obesità, ASL 6 D.S. 1 Cefalù, Palermo, Italy.
BACKGROUND AND AIM: Constipation is one of the most common disorders in Western countries and it is known that dietary factors such as a low fiber diet and low caloric intake are associated with this condition. Weight loss can disrupt the intestinal ecosystem resulting in intestinal dysbiosis that worsens constipation. The aim of this study was to evaluate the effects of treatment with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight) on chronic constipation in patients undergoing a weight loss diet.
Myths and misconceptions about chronic constipation.
Am J Gastroenterol. 2005; 100(1):232-42 (ISSN: 0002-9270)
Müller-Lissner SA; Kamm MA; Scarpignato C; Wald A
Abteilung Innere Medizin, Park-Klinik Weissensee, Schönstrasse 80, 13086 Berlin, Germany.
There are many strongly held beliefs about constipation that are not evidence based. The purpose of this review is to address these beliefs concerning various aspects of constipation. There is no evidence to support the theory that diseases may arise via "autointoxication," whereby poisonous substances from stools within the colon are absorbed. Dolichocolon, defined as an elongated colon, should not be seen as a cause of constipation.
Constipation in long-term care.
J Am Med Dir Assoc. 2007; 8(4):209-18 (ISSN: 1538-9375)
Tariq SH
Division of Geriatric Medicine, Saint Louis University, St Louis, MO 63104, USA. Tariqsh@slu.edu
Constipation is more common in older adults and accounts for increased physician office visits and hospital admissions. There is lack of agreement on the definition of constipation regarding what patients perceive as constipation and what physicians traditionally see as constipation. Constipation is related to multiple factors, and when left untreated or not properly treated, results in complications, such as impaction, even perforation and death.
